Cipla company profile
Company profile
Cipla has 31,369 employees and is headquartered in Mumbai, India.
Customers in India, the United States and South Africa, along with buyers in other countries, are the markets this Mumbai-based drugmaker serves. Its products include off-patent medicines sold as generics and under its own brand names, alongside vaccines and the active ingredients used to make finished drugs. The range covers treatments for respiratory conditions, HIV/AIDS, heart and kidney disease, diabetes, oncology, child health and critical care, and the company also runs consumer healthcare, biosimilars and specialty businesses.
In the fiscal year ended March 2026, revenue reached INR 278.3 billion, up 2.1% from the previous year, and net profit was INR 38.8 billion. The company has 31,369 employees. It was incorporated in 1935 and is headquartered in Mumbai, India.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- India
- Headquarters
- Cipla House, 400013, Mumbai
- Employees
- 31,369
- Chief executive
- Achin Gupta
- Founded
- 1935
- Fiscal year
- April - March
- Listing
- CIPLA · NSE
- Currency
- INR
- ISIN
- INE059A01026
- Website
- cipla.com
Cipla and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| CiplaCIPLA | India | $12.34B | 31,369 | 13.0% | 39.5 |
| Zhejiang NHU002001 | China | $11.61B | 11,508 | 33.8% | 10.6 |
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
